GH Research PLC (GHRS) — GH Research said it would present new Phase 2b data on its inhaled 5-MeO-DMT candidate GH001 for treatment-resistant depression at the American Society of Clinical Psychopharmacology (ASCP) annual meeting in Miami.
The presentations cover multiple posters from the GH001-TRD-201 study, including efficacy by prior antidepressant failure and effects on anhedonia. The disclosure keeps investor attention on GH001 as the company advances toward a global Phase 3 program in 2026.
Source: tipranks.com
For the rest of that week's sector news, read our week in review.